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Background: The prognosis of pulmonary hy-
pertension (PH), especially idiopathic pulmonary
arterial hypertension (IPAH), has improved
 during the recent years. The Swiss Registry for
PH represents the collaboration of the various
centres in Switzerland dealing with PH and serves
as an important tool in quality control. The ob-
jective of the study was to describe the treatment
and clinical course of this orphan disease in
Switzerland.
Methods: We analyzed data from 222 of 252
adult patients, who were included in the registry
between January 1999 and December 2004 and
suffered from either PAH, PH associated with
lung diseases or chronic thromboembolic PH
(CTEPH) with respect to the following data:
NYHA class, six-minute walking distance (6-
MWD), haemodynamics, treatments and survival.
Results: If compared with the calculated ex-
pected figures the one, two and three year mean
survivals in IPAH increased from 67% to 89%,
from 55% to 78% and from 46% to 73%, respec-
tively. Most patients (90%) were on oral or in-
haled therapy and only 10 patients necessitated
lung transplantation. Even though pulmonary
 endarterectomy (PEA) was performed in only 
7 patients during this time, the survival in our
CTEPH cohort improved compared with litera-
ture data and seems to approach outcomes usually
seen after PEA. The 6-MWD increased maxi-
mally by 52 m and 59 m in IPAH and CTEPH,
respectively, but in the long term returned to or
below baseline values, despite the increasing use
of multiple specific drugs (overall in 51% of
IPAH and 29% of CTEPH).
Conclusion: Our national registry data indicate
that the overall survival of IPAH and presumably
CTEPH seems to have improved in Switzerland.
Although the 6-MWD improved transiently, it
decreased in the long term despite specific and
increasingly combined drug treatment. Our find-
ings herewith underscore the progressive nature
of the diseases and the need for further intense re-
search in the field.
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hypertension; endothelin receptor antagonists; bosen-
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CTEPH Chronic thromboembolic pulmonary hypertension
IPAH Idiopathic pulmonary artery hypertension
NYHA New York Heart Association
PAH Pulmonary arterial hypertension
PEA Pulmonary endarterectomy
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6-MWD 6-minute walking distance
SVO2 Mixed venous oxygen saturation
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The Swiss PH Registry was opened in 1999 and in-
cludes prospective patient data from nine Swiss Hospitals
(all five university hospitals and four cantonal hospitals).
All patients provide written informed consent. PH is 
defined as a mean pulmonary artery pressure (mPAP) of
>25 mm Hg at rest or >30 mm Hg at exercise, and a pul-
monary arterial occlusion pressure >15 mm Hg [10]. Ac-
cording to the current clinical classification [1] patients
are grouped in the following classes: 1. PAH 2. PH due to
left heart disease 3. PH associated with chronic lung dis-
ease, 4. CTEPH, 5. PH due to miscellaneous disorders.
The following data were collected: age, gender, diagnosis
according to the clinical classification [1], date of PH di-
agnosis, height, weight, blood pressure, heart rate and
oxygen saturation at rest, NYHA class, six-minute walk-
ing distance (6-MWD), haemodynamics assessed by right
heart catheterization: (mPAP), cardiac output (CO), right
atrial pressure (RAP), mixed venous oxygen saturation
(SvO2), current medication and survival. 
For the present paper, we analyzed data from 252
adult patients (>18 years of age) who were included in 
the registry between January 1999 and December 2004.
Of these, 30 patients were excluded for the following rea-
sons: (1.) patients with PH due to left heart disease (as this
registry focuses on precapillary PH, n = 2), (2.) patients
with various rare medical conditions (class 5) (n = 9), and
(3.) patients without follow-up data (n = 19). Thus, overall
data from 222 patients were available for analysis
(figure 1). Data collection included patients providing
data at the following three time points: 1. the first visit of
the patient (baseline = BL), 2. the visit at the time of the
best 6-MWD (best), as the 6-MWD is used as the pri-
mary end-point in most clinical trials in PH and we
hoped to obtain some information about the maximal
achievable improvement under therapy, and at the last
visit (last). Patients’ survival was completed at the time of
death, or censored at the time of the last observation, pul-
monary endarterectomy (PEA) or transplantation. We
compared survival observed in the subset of 76 IPAH pa-
tients with the expected survival calculated for each pa-
tient based on the NIH formula [4]. This US national
prospective trial with 194 patients with idiopathic PH es-
timates from a proportional hazards model, an equation
to predict a patient’s chance of survival. This NIH for-
mula is calculated as follows: P(t) = [H(t)]A(x,y,z), where
A(x,y,z) = EXP (0.007325x+0.0526y–0.3235z), x is mean
pulmonary artery pressure, y is mean right atrial pressure,
and z is cardiac index. The probabilities of survival at 1, 2,
Pulmonary hypertension (PH) comprises a
group of orphan diseases with a poor prognosis if
untreated. The revised Venice classification [1] in-
cludes pulmonary arterial hypertension (PAH)
and chronic thromboembolic PH (CTEPH) as
the main classes that intrinsically afflict the pul-
monary circulation thereby distinguishing them
from PH due to left heart disorders or chronic
hypoxaemia. PAH is histologicaly characterized
by proliferation and myofibrotic remodelling of
small pulmonary artery vessel walls and can be
subdivided into idiopathic (IPAH) and familial
PAH, such as PAH associated with other condi-
tions (collagen vascular disease, congenital heart
disease, portal hypertension, HIV infection, drug
or substance abuse). CTEPH can affect the prox-
imal or distal pulmonary arteries. Patients with a
proximal CTEPH can be treated by pulmonary
endarterectomy (PEA) [2]. This highly complex
operation is performed only in a few centres
worldwide and in Switzerland, it has only recently
become available in collaboration with the
 German centre. However, CTEPH may share
common vasoreactivity properties with PAH and
hence be amenable to vasodilator treatment [3].
Before the availability of specific therapy, the
median survival of IPAH was 2.8 years, with one
and three year survival of 68% and 48% [4].
Based on these data from the US registry an equa-
tion including the pulmonary artery pressure,
right atrial pressure and cardiac index was devel-
oped to predict survival (NIH formula).
Since the introduction of intravenous
epoprostenol in 1995, the 1 and 3 year survival
rates have increased to 88% and 68%, respec-
tively [5]. Epoprostenol treatment, however, was
limited by the necessity of continuous intra-
venous infusion through a central venous line
prone to various complications and therefore has
rarely been used in Switzerland [6]. Advances in
diagnosis and new therapeutic options including
inhaled iloprost [7], oral bosentan [8] and silde-
nafil [9] have created an increased interest in PH.
The first report from the Swiss Registry on pa-
tients with PH in Switzerland dates from 2001
[6]. In this article we present an update on treat-
ment, clinical course and survival of patients with
PH in Switzerland. 
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Introduction
Material and methods
Figure 1
Enrolment and Dispo-
sition of Subjects. 
PAH: Pulmonary
 arterial hypertension,
WHO-Venice class V:
Pulmonary hyperten-
sion caused by  dis -
orders directly affect-
ing the pulmonary
vasculature, CTEPH:
Chronic  thrombo -
embolic pulmonary
 hypertension.
Swiss PH Registry 1/1999 to 12/2004
>18 years (n = 252)
Included in the study
(n = 222)
PAH (n = 139)
PH associated with 
lung disease (n = 17)
CTEPH
(n = 66)
Excluded (n = 30)
Left heart disease (n = 2)
Pulmonary angiosarcoma (n = 3)
WHO-Venice class V (n = 6)
Lack of follow-up (n = 19)
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and 3 years are given by the following: P(1) = 0.75A; P(2)
= 0.65A; and P(3) = 0.55A.
All results are expressed as means (standard devia-
tions). Statistical analysis was performed using SPSS ver-
sion 12.0.1 software package. The paired T-test was used
for continuous variables and the Chi square test for
 discrete variables. Kaplan-Meier statistics was used to es-
timate overall survival. A p value <0.05 was considered to
be significant.
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Results
The baseline characteristics of the 222 pa-
tients included in the current analysis are shown
in table 1. The mean follow-up was 24 (17)
months (range 1–70). The time between the base-
line and the best values was 12 (13) months, and
the time between best and last values 12 (13)
months. Mean age was 57 (16) years and 60% of
the patients were female. The mPAP was not
 significantly different in patients with IPAH and
those with CTEPH [51 (18) respectively 46 (13)
All patients IPAH CTEPH CVD HIV Lung Others
(n = 222) (n = 76) (n = 66) (n = 33) (n = 10) (n = 17) (n = 20)
Age in years (SD) 57 (16) 55 (17) 63 (13) 57 (15) 44 (13) 63 (11) 48 (19)
Female sex (n) 134 (60%) 52 (68%) 37 (56%) 23 (70%) 4 (40%) 6 (35%) 12 (60%)
Body mass index in kg/m2 (SD) 26 (7) 27 (8) 26 (5) 24 (5) 21 (3) 26 (4) 26 (7)
NYHA functional class (n)
– Class I 1 (0.5%) 1 (3%)
– Class II 24 (11%) 7 (8%) 9 (14%) 3 (9%) 2 (12%) 2 (10%)
– Class III 144 (65%) 53 (71%) 40 (61%) 20 (61%) 1 (10%) 8 (47%) 15 (75%)
– Class IV 53 (23%) 16 (21%) 17 (25%) 9 (27%) 9 (90%) 7 (41%) 3 (15%)
6-MWD in m (SD) 356 (142) 353 (139) 364 (146) 359 (157) 395 (109) 311 (146) 351 (139)
mPAP in mm Hg (SD) 49 (17) 51 (19) 46 (13) 44 (13) 48 (10) 47 (15) 64 (23)
RAP in mm Hg (SD) 9 (7) 10 (8) 10 (6) 7 (5) 6 (4) 7 (4) 11 (7)
CO in L/min (SD) 4.1 (1.3) 4.2 (1.3) 3.7 (1.0) 4.0 (1.1) 3.9 (1.2) 4.5 (1.0) 5.1 (2.0)
SVO2 in % (SD) 59 (11) 61 (10) 58 (7) 58 (16) 59 (6) 55 (18) 64 (8)
IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension,
CVD: Collagen vascular disease, HIV: Human immunodeficiency virus infection, Lung: Pulmonary Hypertension associated with lung
diseases and/or hypoxemia, Others: Other causes of pulmonary artery hypertension,  NYHA: New York Heart Association, 6-MWD:
6-minute walking distance, mPAP: mean pulmonary artery pressure, RAP: mean right atrial pressure, CO: mean cardiac output, 
SVO2: mixed venous oxygen saturation
Data are given as means, standard deviation (SD) and percentages (%) 
Table 1
Baseline characteris-
tics of the whole
 patient population 
(n = 222).
C
u
m
 S
u
rv
iv
a
l
Years
No. at Risk
IPAH 76 59 38 19 7 4
CTEPH 66 42 28 13 8 5
CVD 33 22 10 5 1
Lung 17 4 1
HIV 10 6 4
Figure 2
Kaplan-Meier esti-
mates of survival in
patients with PH in
Switzerland. There
was no significant
difference in survival
of the main three
WHO groups in-
cluded in the current
analysis. Compared
with IPAH, patients
suffering from PAH
associated with colla-
gen vascular dis-
eases (CVD) and HIV
disease had a signifi-
cantly worse survival
(p = 0.034 and p =
0.027, respectively).
IPAH: Idiopathic pul-
monary artery hyper-
tension, CTEPH:
Chronic thrombo -
embolic pulmonary
hypertension, CVD:
Collagen vascular
disease, Lung: Pul-
monary Hypertension
associated with lung
diseases and/or
 hypoxaemia.
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mm Hg; p = 0.16]. During the observation period,
147 patients survived, 10 underwent lung trans-
plantation, 7 PEA and 58 died. The 1, 2, 3 and 5
year survival of the whole population was 85%,
74%, 71%, and 53%, respectively. There was no
difference in survival between patients with PAH,
CTEPH or patients with lung diseases (figure 2).
Compared with IPAH, patients suffering from
PAH associated with connective tissue diseases
and HIV had a significantly worse survival (p =
0.034 and p = 0.027, respectively).
When compared to the expected survival cal-
culated according to the NIH formula, the 1, 2,
and 3 year mean survival for patients with IPAH
increased from 67% to 89%, from 55% to 78%
and from 46% to 73% and was comparable with
other investigated cohorts (figure 3) [5, 12]. For
further analysis concerning treatment, only the
major patient groups IPAH (n = 76) and CTEPH
(n = 66) were included. At baseline, most patients
were in NYHA class III (65%) and IV (24%) with
no difference between the two groups. Follow-up
data of patient allocation to NYHA classes are
shown in table 2. Initially, medical care seemed 
effective, a significant improvement from baseline
to best with more IPAH patient being in NYHA
class I or II compared to III was found (p = 0.025).
In the long term, patients seemed to either re-
spond or not respond to therapy, as the number of
NYHA class III patients decreased significantly
from baseline to the last visit at the expense of
class II (therapy-responders) and class IV (non-
responders). There was a similar trend in
CTEPH, although it seemed that the percentage
of non-responders was somewhat higher in this
group (table 2).
Therapy seemed also to be effective initially
as regards exercise capacity measured by the 6-
MWD, which significantly increased from base-
line to best in both IPAH and CTEPH (p <0.001
for both groups, figure 4). However, this consid-
erable improvement could not be maintained in
the long-term as the 6-MWD declined to base-
line values in both groups (p >0.001 between best
and last, p = ns between baseline and last for all
groups, figure 4).
Treatments are divided into basic (oxygen, di-
uretics, oral anticoagulation) and PH-specific
(prostanoids, endothelin receptor antagonists and
phosphodiesterase-5 inhibitors) as well as into
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Figure 3
Kaplan-Meier esti-
mates of survival 
in patients with IPAH 
in Switzerland com-
pared with the 
expected survival 
according to the NIH
formula [4] and litera-
ture data [5, 12].
IPAH: Idiopathic pul-
monary artery hyper-
tension.
Baseline Best Last
IPAH CTEPH IPAH CTEPH IPAH CTEPH
NYHA 1 (%) 0 0 1 6 4 4
NYHA 2 (%) 8 14 23 20 19 14
NYHA 3 (%) 69 60 48 40 37 44
NYHA 4 (%) 23 26 28 34 40 38
IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary 
hypertension, NYHA: New York Heart Association
Table 2
Percentages of NYHA
functional classes in
patients with IPAH 
(n = 65) and CTEPH 
(n = 50), in whom
data at all three time
points were avail-
able.
Baseline Best Last
440
420
400
380
360
340
320
300
6
-M
W
D
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m
)
IPAH
CTEPH
p <0.001p <0.001
Figure 4
Changes in 6-MWD
over time in patients
with IPAH (n = 59)
and CTEPH (n = 45),
in whom data at all
three time points
were available. The
difference between
baseline and best as
well as between best
and last, respectively,
was significant at the
same P values for
both IPAH and CTEPH
(P <0.001 for all 
comparisons).
IPAH: Idiopathic pul-
monary artery hyper-
tension, CTEPH:
Chronic  thrombo -
embolic pulmonary
hypertension, 6-MWD:
6-minute walking 
distance.
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uretics, oral anticoagulation) and PH-specific
(prostanoids, endothelin receptor antagonists and
phosphodiesterase-5 inhibitors) as well as into
single (only one specific drug) and multiple (more
than one specific drug) medications.
The basic treatment at all time points is
shown in table 3. Basic therapy was broadly ap-
plied in all groups. At the last visit 40% of all pa-
tients (IPAH + CTEPH) were on oxygen, 54% on
diuretics and 87% on oral anticoagulation, with
no major differences between the groups. In the
CTEPH group all but one (haemophilia patient,
65/66) were receiving oral anticoagulation at
their last visit. From baseline to the time of the
best 6-MWD there were marked increases in the
use of oxygen, diuretics and oral anticoagulation
in all groups.
The percentage of patients receiving specific
therapy significantly increased from baseline to
the last visit; from 31% to 89% in patients with
IPAH and from 31% to 81% in CTEPH. The
overall number of patients receiving each of the
five specific treatment modalities including multi-
ple therapies is shown in table 4.
Regarding the drugs used for single specific
therapy, there was a tendency towards a decreased
use of inhaled iloprost over time in both group
and a tendency towards an increased use of
bosentan in CTEPH patients. 
From baseline to best, respectively last visit,
there was a steady increase in the use of multiple
specific drugs (from 4% to 29% respectively 51%
in IPAH patients, and from 4% to 16% respec-
tively 29% in CTEPH patients). Considering the
various combination treatments (table 4), the
most frequently applied combination in IPAH
was inhaled iloprost with bosentan and in
CTEPH inhaled iloprost with sildenafil. More
than a quarter of the IPAH patients were on three
or more drugs at the last visit. 
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Oxygen (%) Diuretics (%) OAK (%)
IPAH CTEPH IPAH CTEPH IPAH CTEPH
Baseline 25 22 33 36 59 79
Best 41* 30 43 55* 84** 89
Last 42 38 49 61 84 98
IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic  thromboembolic pulmonary hypertension, 
OAK = oral anticoagulation. *p <0.05; **p <0.001
Table 3
Basic treatments at
the three time points.
IPAH CTEPH
BL Best Last BL Best Last
Specific 26 of 83 63 of 75 67 of 75 22 of 70 44 of 60 46 of 57
Therapy* (31%) (84%) (89%) (31%) (73%) (81%)
Single drug
CCB (%) 8 2 0 9 5 4
Ilo inh (%) 50 22 16 71 51 30
Ilo iv (%) 8 6 5 4 0 2
Bos (%) 30 37 25 15 23 26
Sil (%) 0 4 3 0 5 9
Multiple drugs
Bos+Sil (%) 0 2 5 4 2 7
Bos+Ilo (%) 4 19 16 0 7 7
Ilo+Sil (%) 0 2 3 0 5 13
3 and > (%) 0 6 27 0 2 2
IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, 
BL = Baseline, CCB: Calcium Channel Blocker, Ilo inh: Ilomedin inhalation, Ilo iv: Ilomedin intravenous, 
Bos: Bosentan, Sil: Sildenafil, * Overall number of patients on specific drug therapy
Table 4
Single and multiple
specific drug therapy
(percentages) at the
three time points in
IPAH and CTEPH
 patients.
Discussion
The present study summarizes the therapeu-
tic management and clinical course of PH patients
from the Swiss registry. The overall survival in the
present PH cohort was 71% at three and 53% at
five years. Whereas survival of patients with IPAH
and CTEPH as well as those with PH associated
with lung diseases was comparable, prognosis of
PAH associated with connective tissue diseases
and HIV infection was significantly worse. This is
in line with the previously published cohorts. In a
recent series of 91 patients receiving continuous
intravenous epoprostenol treatment, the 3-year
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survival was 65% in IPAH patients compared
with only 34% in patients with PAH associated
with connective tissue diseases [14] thus confirm-
ing earlier data showing the dismal prognosis of
these patients [15]. Data from the Swiss HIV Co-
hort showed lower survival of patients with
mostly untreated HIV-related PAH (median 1.3
years) compared with matched HIV-infected pa-
tients without PAH (median 2.6 years) [16]. Simi-
larly, a recent series of 82 patients with HIV-re-
lated PAH receiving treatment with intravenous
epoprostenol (24%) and/or combination anti-
retroviral therapy (48%) confirmed a poor 3 year
survival (47%) [17]. Regarding only those IPAH
patients for whom the most survival data are
available, the one year survival in our cohort was
89%, which is similar to the one year survival
found in the French national registry [18]. How-
ever, our IPAH 3 year survival rate of 73% is
much better than the expected figure (46%) cal-
culated using the PH-survival formula including
various haemodynamic parameters based on a his-
torical NIH cohort [4]. Although a certain im-
provement in survival compared with historical
cohorts can be expected due to advances in gen-
eral patient care and ameliorated living circum-
stances, the magnitude seen here suggests an ef-
fect of PH specific therapy. Remarkably, only 
10 patients in the present cohort needed lung
transplantation. This is even more surprising con-
sidering the fact that only seven patients in our se-
ries were receiving continuous intravenous
prostaglandin treatment and that the prognosis
was nonetheless comparable with recently de-
scribed similar cohorts [5, 12]. This might sug-
gest that modern oral or inhaled specific treat-
ment options, including combination therapies,
may be as effective as intravenous prostaglandins
alone [19–22] whilst avoiding the complications
frequently associated with intravenous lines and
pump systems. The effectiveness of specific non-
invasive combination therapies may be the reason
why only a minority of the NYHA IV patients in
our cohort received intravenous iloprost, despite
international recommendations [23]. In addition,
this may be especially true for patient groups with
a previously unfavourable prognosis such as HIV,
since a recent open label trial in 16 HIV patients
demonstrated an improvement in exercise capac-
ity, haemodynamics and quality of life with no
deaths after 3 months of bosentan therapy [24]. 
Oxygen therapy improves cardiac index and
pulmonary vascular resistance in patients with
PH [25] but there are no data showing that long-
term supplemental oxygen is beneficial in pul-
monary hypertension with or without hypox-
aemia. At the last time point 42% of our IPAH
patients were on oxygen therapy. This is rather a
high number compared with Breathe-1 (33%)
and STRIDE-1 (30%). There may be an overuse
in Switzerland and this must be better monitored.
Available data on drug treatment based on pul-
monary hypertension registries are very limited.
In an Israeli study on IPAH patients most were on
anticoagulation at the first registration (95% vs.
59% in our study) but only 13% were already
treated with prostacyclins (compared with 20% in
our study) [26]. At baseline, 31% of the IPAH pa-
tients were on specific drug medication (20% on
prostaglandins and 9% on bosentan). These data
differ from a large American cohort on patients
with PAH, where  31% of patients were on cal-
cium channel blockers at the time of referral and
only a small number on prostaglandins (2.4%) or
bosentan (3.1%) [27]. 
Our favourable survival data might be ex-
plained by the introduction of specific vasodilator
combination therapy. As shown in figure 4, after
one year of treatment the 6-MWD improved by
52m and 59m in IPAH and CTEPH, respectively.
These figures are comparable to those reported in
the recent large randomized trials [7–9, 28]. After
another year, however, the 6-MWD had de-
creased to the baseline levels, emphasizing the
fact that these disorders exhibit a relentlessly pro-
gressive nature. At this time point more than half
of the IPAH patients and almost one third of
those with CTEPH were on combination ther-
apy, predominantly inhaled iloprost and bosentan
in IPAH, and inhaled iloprost and sildenafil in
CTEPH of patients. So far, there are numerous
case series of mainly PAH patients demonstrating
a potential benefit of vasodilator combination
therapy [29–33]. After the first randomized trial
of bosentan added on to intravenous epoprostenol
failed to show a benefit [34], probably due to the
insufficient number of patients included, a recent
randomized study on the addition of inhaled ilo-
prost to bosentan revealed a significant improve-
ment in the 6-MWD, a decrease in NYHA func-
tional class and a delayed time to clinical worsen-
ing in the treatment group [35].
Until recently it was thought that CTEPH
has a better prognosis than IPAH. Kunieda et al.
compared 48 untreated CTEPH-patients with 32
untreated IPAH-patients and found a survival of
73% and 43% at 3 years, respectively, and 44%
and 23% at 6 years, respectively [36]. CTEPH
patients are believed to respond poorly to va-
sodilator therapy attributed to a more fixed vessel
obstruction by clots and reactive fibrotic remod-
elling of the more proximal pulmonary artery ves-
sel wall. On the other hand, the course of the de-
velopment of CTEPH possibly differs from other
PH-forms. Furthermore CTEPH is the only po-
tentially curable PH-form. The observation of an
almost super imposable survival curve of CTEPH
and IPAH patients in the current series might 
be surprising. It is, however, well known that
CTEPH may show microvascular changes com-
parable to IPAH, including plexiform lesions [37].
In addition, a recent study has shown that
CTEPH and IPAH may share vasoreactive prop-
erties [3]. Remarkably, the survival of our
CTEPH cohort (from which only seven under-
went PEA) was only slightly lower than that of
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the 532 patients who underwent PEA at the
world’s largest centre in San Diego [38].
The present study based on national registry
data has a number of limitations. As noted in the
methods section one of our chosen time point is
the “best 6-MWD”. This is somewhat arbitrary
and might favour statistically significant results
between this point and BL or the last visit. How-
ever, it was our intention to gain insight into the
maximal possible therapeutic effect. Therefore we
choose the 6-MWD as the most widely used end-
point of clinical trials. This enables us to compare
our registry data, which are likely to represent or-
dinary clinical practice, with the results of ran-
domized controlled trials in the field. The selec-
tion of the time of the best 6-MWD as a further
data point also provided us with an additional and
more complete data set. This would not have
been the case if we had chosen another fixed time
point (e.g. one year after therapy). Although
prospectively entered, registry data collection is
not scheduled prospectively as in proper clinical
trials but  reflects every day clinical practice
where patients are scheduled based on the well
being, illness, social and occupational availability
of both patients and health care providers. There-
fore, registry data might be flawed by missing or
inconstant parameters. In comparison with clini-
cal trials, every patient with the disease can be en-
tered in the registry regardless of co-morbidities.
However registry entering is voluntary and there-
fore some PH-patients might be unidentified.
Summarizing the drawbacks and advantages, we
believe that nation wide registry data including a
broad patient collective (presumably also multi-
or comorbid patients, who would never be entered
in a randomized study) provide important infor-
mation for health care providers in the field.
In conclusion, these data retrieved from the
Swiss PH Registry describe the management of
patients with PH in Switzerland with emphasis on
the major groups IPAH and CTEPH. They
 indicate an improvement in prognosis of these
 patients in the recent years, including a low per-
centage of patients necessitating intravenous
prostaglandin therapy or lung transplantation.
 Interestingly, patients with CTEPH exhibited a
similar improvement in prognosis under standard
vasodilator therapy. Our findings encourage the
thorough maintenance and complementation of
the Swiss PH registry in order to acquire high
quality surveillance data of PH patient care in the
future.  
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